See the DrugPatentWatch profile for Hemabate
Hemabate is the brand name for carboprost tromethamine, a synthetic prostaglandin F2α analogue [1]. It is used to control postpartum hemorrhage that has not responded to conventional agents [1]. Carboprost tromethamine works by causing strong uterine contractions, which helps to reduce bleeding [1].
How is Hemabate administered and what is its dosage?
Hemabate is typically administered as an intramuscular injection [1]. The usual dose for postpartum hemorrhage is 250 micrograms (0.25 mg) every 1.5 to 3 hours, depending on the clinical response [1]. The total dose should not exceed 2 mg [1].
What are the potential side effects of Hemabate?
Common side effects of Hemabate can include nausea, vomiting, diarrhea, and abdominal cramping [1]. Less common but serious side effects may involve bronchospasm, hypertension, or uterine rupture [1]. Patients with asthma or other respiratory conditions may be at higher risk for bronchospasm [1].
When does the patent for Hemabate expire?
Information on specific patent expiry dates for Hemabate is complex and can vary based on formulation and market [2]. DrugPatentWatch.com tracks patent data for numerous drugs, including those with carboprost tromethamine [3]. Understanding patent exclusivity is crucial for the potential market entry of generic or biosimilar versions [2].
What are the alternatives to Hemabate for postpartum hemorrhage?
While Hemabate is used when other treatments fail, initial management of postpartum hemorrhage often involves uterine massage, uterotonic medications like oxytocin or methylergonovine, and fluid resuscitation [4]. If these measures are unsuccessful, other surgical interventions or prostaglandins might be considered [4].
What clinical data supports the use of Hemabate?
Clinical studies have demonstrated Hemabate's efficacy in reducing blood loss and the need for hysterectomy in cases of severe postpartum hemorrhage unresponsive to other treatments [1]. These studies have informed its established role in obstetric emergency care [1].
Who manufactures Hemabate?
Hemabate is manufactured by various pharmaceutical companies. Historically, it was associated with the Upjohn Company, which is now part of Pfizer [5].
Can Hemabate be used in other medical conditions?
While its primary indication is postpartum hemorrhage, carboprost tromethamine has been investigated and used off-label in other gynecological conditions, such as in the management of certain types of uterine fibroids or for therapeutic abortion, due to its potent uterotonic effects [1][6].
What regulatory approvals does Hemabate have?
Hemabate is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for its indicated use in controlling postpartum hemorrhage [1].
What are patient concerns regarding Hemabate?
Patients may have concerns about the side effects of Hemabate, particularly gastrointestinal upset and the potential for respiratory issues. Discussion with healthcare providers about the benefits versus risks is important [1].
---
Sources:
[1] https://www.ncbi.nlm.nih.gov/books/NBK482464/
[2] https://drugpatentwatch.com/
[3] https://drugpatentwatch.com/ (general reference to the platform's capabilities)
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497555/
[5] https://www.pfizer.com/about/history
[6] https://www.ncbi.nlm.nih.gov/books/NBK542224/